Ångström AI
Gen AI molecular simulations that reproduce wetlab results
Based based in San Francisco, CA, USA, Ångström AI works in healthcare.
Profile
Angstrom AI builds GenAI-based molecular simulations to substitute wet lab experiments in the pre-clinical drug development pipeline. We are a team of 2 PhD's and 2 Professors from the University of Cambridge who decided to start a company together after we realised how to combine breakthoughs in our research in quantum-accurate models of physics and generative AI models.
Our Biotech/Pharma clients can verify the efficacy and safety of new drug candidates using our computer simulations, which match the accuracy of wet lab experiments, but are over 100x faster. We achieve this accuracy by constraining our genAI-based simulations to obey the laws of physics, avoiding the hallucinations seen in other GenAI technologies.
Since joining YC, Angstrom AI has developed the first physically accurate gen-AI based simulation of multiple molecules interacting. We have published the first molecule water solubility results with accuracy within the error range of wet lab experiments. We have also kicked-off a 150K pilot project with a pharma company to apply our tech to estimating solubility in their drug development pipeline.
Within the healthcare space, the company focuses on its core offering rather than a broad product line.
The business is associated with San Francisco, CA, USA.
Its current recorded stage is Summer 2024.
Its team size is recorded as 5 employees.
Directory analysis
Ångström AI develops generative AI‑driven molecular simulations that replicate wet‑lab experiments, aiming to accelerate pre‑clinical drug development. The startup combines quantum‑accurate physics models with AI to produce simulations that are reportedly over 100× faster than traditional wet‑lab testing. Its team, composed of Cambridge PhDs and professors, targets biotech and pharma clients seeking faster efficacy and safety validation.
Positioning: Ångström AI positions itself at the intersection of AI and drug discovery, offering a computational alternative to expensive wet‑lab experiments. While its technology promises speed gains, its adoption will depend on validation against industry standards and integration into existing development pipelines.
Note: The company claims its simulations match wet‑lab accuracy while being significantly faster.
Auto-generated directory analysis from public data · updated 12 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 5 |
| Stage | Summer 2024 |
Website: www.angstrom-ai.com
Browse related
Create a free account